Page 89 - Read Online

Lorenzin et al. J Transl Genet Genom 2019;3:5. I https://doi.org/10.20517/jtgg.2019.01 Page 11 of 12

81. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, et al. Challenges in recognizing treatment-related neuroendocrine prostate
cancer. J Clin Oncol 2012;30:e386-9.
82. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res
2014;20:2846-50.
83. Wang HT, Yao YH, Li BG, Tang Y, Chang JW, et al. Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic
adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled
analysis. J Clin Oncol 2014;32:3383-90.
84. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, et al. Clinical and genomic characterization of treatment-emergent small-cell
neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 2018;36:2492-503.
85. Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, et al. Androgen receptor pathway-independent prostate cancer is
sustained through FGF signaling. Cancer Cell 2017;32:474-89.e6.
86. Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model
of castration-resistant prostate cancer. Cancer Discov 2017;7:736-49.
87. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate
cancer. Nat Med 2016;22:298-305.
88. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and
antiandrogen resistance. Science 2017;355:78-83.
89. Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and
RB1-deficient prostate cancer. Science 2017;355:84-8.
90. Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed
driver of neuroendocrine differentiation in prostate cancer. Cancer Discov 2017;7:54-71.
91. Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, et al. Reprogramming normal human epithelial tissues to a common, lethal
neuroendocrine cancer lineage. Science 2018;362:91-5.
92. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, et al. Molecular characterization of neuroendocrine prostate cancer and identification
of new drug targets. Cancer Discovery 2011;1:487-95.
93. Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, et al. N-Myc induces an EZH2-mediated transcriptional program driving
neuroendocrine prostate cancer. Cancer Cell 2016;30:563-77.
94. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol
2008;32:65-71.
95. Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, et al. SPINK1 defines a molecular subtype of prostate cancer in men with more
rapid progression in an at risk, natural history radical prostatectomy cohort. J Urol 2016;196:1436-44.
96. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, et al. Association of SPINK1 expression and TMPRSS2:ERG fusion
with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010;16:2845-51.
97. Pan X, Zhang X, Gong J, Tan J, Yin X, et al. The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic
prostate cancer. Prostate 2016;76:823-33.
98. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer
Cell 2008;13:519-28.
99. Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, et al. Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer
mediates castration resistance. Cancer Cell 2017;32:792-806.e7.
100. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate
2000;45:323-34.
101. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998;58:2520-3.
102. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced
metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 2004;101:1345-56.
103. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate
growth and tumorigenesis. Oncogene 2002;21:2679-94.
104. Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res
2000;60:4709-13.
105. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002;277:11336-
44.
106. Nava Rodrigues D, Casiraghi N, Romanel A, Crespo M, Miranda S, et al. RB1 heterogeneity in advanced metastatic castration-resistant
prostate cancer. Clin Cancer Res 2019;25:687-97.
107. Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, et al. Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA
PCAT19. Cell 2018;174:564-75.e18.
108. Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA, et al. Role of non-coding sequence variants in cancer. Nat Rev Genet
2016;17:93-108.
109. Gao P, Xia JH, Sipeky C, Dong XM, Zhang Q, et al. Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility
locus. Cell 2018;174:576-89.e18.
110. Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, et al. Inherited determinants of early recurrent somatic mutations in prostate